Cardinal Health, Inc. Stock 12‑Month Price Target Raised to $304.07, Implies 9% Upside
The average 12-month price target for Cardinal Health, Inc. (CAH) stock has increased from $302.47 to $304.07, with forecasts ranging from $265 to $330 per share from 14 analysts. This updated target suggests approximately 9% potential upside based on the Nov. 18 closing price. The consensus rating among 20 analysts remains a "Buy," with 15 Buys, 5 Holds, and 0 Sells.
Gartner ranks healthcare supply chains, led by AdventHealth
Gartner's "Healthcare Supply Chain Top 25 for 2026" report named AdventHealth as the top performer for the third consecutive year, followed by Stanford Medicine, Bon Secours Mercy Health, Corewell Health, and Northwestern Medicine. The leading organizations excelled by accelerating clinical collaboration, strengthening supply chain resiliency, and advancing AI and digital capabilities. These strategies help maintain supply assurance during disruptions and improve day-to-day performance.
Cardinal Health (CAH) Is Facing Multiple Class I Medical Kit Recalls
Cardinal Health (NYSE:CAH) is currently facing multiple Class I medical kit recalls for its Presource PBDS kits containing BD Alaris Pump Infusion Sets due to performance issues. These recalls, affecting over 70,000 kits, are classified as the most serious tier, indicating a possibility of significant health consequences. The situation challenges Cardinal Health's narrative of tight quality controls and will be further assessed in its upcoming quarterly report.
How Baxter Boosts Medical Circularity And Net Zero Targets
Baxter, a leading medical technology company, is striving for both medical circularity and net zero emissions by 2050, despite the challenges of maintaining strict sterility standards for its products. Chief Sustainability Officer Renae Kerzar explains how Baxter integrates material reduction into product engineering, collaborates with healthcare systems to manage waste, and implements a global plan to decarbonize its operations, aiming for 100% clean, renewable electricity by 2040. The company also emphasizes the importance of "double materiality" to align sustainability efforts with financial and risk management goals, and partners with other healthcare organizations to advance circularity and reduce emissions across the supply chain.
Wells Fargo raises Cardinal Health stock price target on pharma strength
Wells Fargo has increased its price target for Cardinal Health (NYSE:CAH) shares to $321 from $277, maintaining an Overweight rating due to strong performance in the pharmaceutical and other segments. The firm also raised its earnings per share estimates for fiscal years 2027 and 2028. This adjustment follows Cardinal Health's impressive first-quarter fiscal 2027 results and a raised full-year profit outlook.
Citadel Advisors reports 0 Core Scientific (CORZ) shares. Kenneth Griffin may be deemed an owner.
An amended beneficial-ownership report for Core Scientific, Inc. (CORZ) indicates that Citadel Securities LLC may own 2.5% of shares, while Citadel Securities GP LLC, Citadel Securities Group LP, and Kenneth Griffin may each be deemed to own 3.5%. Conversely, Citadel Advisors LLC, Citadel Advisors Holdings LP, and Citadel GP LLC all report 0 shares. The ownership percentages are based on 321,341,284 shares, including outstanding shares as of July 23, 2026, and shares issuable from warrants.
Form 4 Cardinal Health Inc: Michelle Brennan (Director) For: 12 November By Investing.com
This article reports on a Form 4 filing for Cardinal Health Inc, specifically detailing a transaction by director Michelle Brennan on November 12. The brief announcement from Investing.com indicates insider trading activity for the company, with its stock symbol CAH mentioned alongside a slight positive price movement.
Form 4 Cardinal Health Inc: Michelle Brennan (Director) For: 12 November
The article reports on a Form 4 filing for Cardinal Health Inc., indicating that director Michelle Brennan made a transaction on November 12. This type of filing is used to report changes in beneficial ownership of a company's stock by insiders. The brief news item notes the stock ticker CAH and its current performance.
Citadel Advisors lists zero shares as Citadel Securities reports a potential AmpliTech (AMPG) stake.
A recent SEC filing (SCHEDULE 13G/A) indicates that Citadel Securities LLC, Citadel Securities Group LP, Citadel Securities GP LLC, and Kenneth Griffin potentially beneficially own 1,179,193 shares, or 3.9%, of AmpliTech Group, Inc. (AMPG) common stock. In contrast, Citadel Advisors LLC, Citadel Advisors Holdings LP, and Citadel GP LLC are listed with zero beneficially owned shares. This disclosure, which clarifies overlapping reports of the same position, highlights the beneficial ownership structure by different Citadel entities.
Revenue rose to $2.05M, but Quanome Technologies (QNME) remained in the red.
Quanome Technologies (QNME) reported increased revenue of $2.05 million for the three months ended September 30, 2026, up from $1.34 million a year earlier, primarily driven by higher sales of infusion products and new customers. Despite the revenue growth and an improved gross profit margin, the company posted a net loss of $664,270 and raised substantial doubt about its ability to continue as a going concern, citing reliance on external financing. The company is also expanding into AI computing infrastructure and evaluating quantum-related technologies, with significant capital expenditure commitments for new equipment.
Kenneth Griffin reports shared, not sole, voting power over Camping World (CWH) shares.
Kenneth Griffin and several Citadel entities have amended their beneficial ownership report for Camping World Holdings, Inc. (CWH) Class A common stock. They each reported zero sole voting and dispositive power, instead indicating shared authority over their respective positions. Kenneth Griffin is deemed to own 1,862,423 shares (2.9%) with shared voting and dispositive power.
Three Wellington entities report identical stakes in Cardinal Health (CAH).
Wellington Management Group LLP, Wellington Group Holdings LLP, and Wellington Investment Advisors Holdings LLP have each reported a 4.26% beneficial ownership stake in Cardinal Health, Inc. (CAH), totaling 9,866,422 shares as of September 30, 2026. The three entities also reported shared voting power over 9,666,541 shares and shared dispositive power over 9,866,422 shares, noting that these identical figures are due to Wellington's ownership structure and are not additive. The shares are ultimately owned by clients of Wellington investment advisers, none of whom individually hold more than 5% of the class.
Form 8K Cardinal Health Inc For: 16 November By Investing.com
This article from Investing.com announces the filing of a Form 8K by Cardinal Health Inc. on November 16, 2026. The 8K filing is a standard requirement for public companies to notify investors of significant events. The article provides minimal detail beyond the announcement itself.
CAH: Cardinal Health Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
Cardinal Health Inc. filed an SEC Form 8-K reporting the results of its annual meeting held on November 12, 2026. Shareholders re-elected all 11 directors, approved executive compensation on a non-binding basis, and ratified Ernst & Young LLP as the independent auditor for fiscal year 2027. The votes were largely one-sided, indicating broad shareholder satisfaction with the board and management.
CAH: Cardinal Health Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
Cardinal Health Inc. filed an SEC Form 8-K reporting the submission of matters to a vote of security holders. Shareholders re-elected all 11 directors and ratified Ernst & Young as the auditor for fiscal 2027 at the annual meeting on November 12. The stock's historical performance after similar headlines shows a median move of 1.4% in either direction.
Cardinal Health (CAH) Gains Fresh Support After Strong Earnings While Fair Value Stays In View
Analyst sentiment for Cardinal Health (CAH) has improved following strong earnings and profit figures, making it an attractive stock for income and healthcare exposure. The company confirmed a quarterly dividend and reported increased sales and net income in its first quarter earnings. While the stock has seen a significant rise, analysts believe it remains modestly undervalued at $281.10 compared to a fair value of $291.53, despite trading at a premium P/E ratio compared to its peers.
Will Strong Quarterly Earnings Change McKesson (MCK) Stock Narrative
McKesson (MCK) reported strong Q2 2026 results with US$110.96 billion in sales and US$1.22 billion in net income, delivering a basic EPS of US$10.47. These earnings reinforce the company's existing narrative of being a high-volume, low-margin healthcare distributor expanding into oncology and access platforms. While the new data supports the operational story, core catalysts and risks, such as regulatory pressures and cyber incidents, remain unchanged, with analysts forecasting continued revenue and earnings growth through 2029.
Two Medical Giants Diverge in Strategy as Investors Face a Choice Between Steady Returns and High Growth
Amgen (AMGN) and Vertex Pharmaceuticals (VRTX) offer investors distinct choices: Amgen provides steady returns with a lower valuation, strong cash flow, and diversified operations, appealing to those seeking stability. Vertex, while growing faster with conservative finances and a promising pipeline, comes with a higher valuation and concentrated revenue. Investors must weigh these differences based on their individual risk and return preferences.
Acetaminophen Market To 2035: Self-Care and Aging Demographics Support Forward Growth - News and Statistics
The global acetaminophen market is projected to experience steady growth through 2035, driven primarily by increasing self-care practices and an aging global population. While demand is underpinned by the universal need for pain and fever relief, the market faces challenges from high private-label penetration, regulatory constraints, and competition from substitutes like ibuprofen. E-commerce and direct-to-consumer channels are expected to continue disrupting traditional pharmacy-centric purchase journeys, with developed markets focusing on innovation and emerging economies on volume expansion.
Cardinal Health, Inc. (CAH) Seasonal returns chart
The article provides a seasonal returns chart for Cardinal Health, Inc. (CAH), displaying the average monthly price return from 2016 to 2026. It includes current stock information, showing CAH at 281.10 USD with a slight increase at close on November 13th. The page also offers various financial data categories for the company, such as news, charts, statistics, and analysis.
Argus raises Cardinal Health stock price target on strong earnings
Argus has raised its price target for Cardinal Health (NYSE:CAH) to $309 from $264, maintaining a Buy rating after the company reported strong first-quarter fiscal 2027 results. The healthcare services company exceeded revenue and adjusted EPS estimates, leading to an upward revision of its fiscal 2027 earnings guidance. Analysts cited consistent segment profit growth, focus on specialty markets, and strong free cash flows as reasons for the increased confidence in the stock.
Alcon Banks On Vivity Pro To Return Implantables To Growth After US Premium IOL Share Loss
Alcon's third-quarter sales increased by 5% to $2.7 billion, but implantables experienced a 2% decline due to heightened competition in the US premium IOL market. To counter this, Alcon is relying on its new Vivity Pro lens, launching in January, an RxSight license, and the recent Neurotech acquisition to stimulate growth and outpace the estimated 3% market expansion. The company aims to restore growth in its implantables business after losing US premium intraocular lens share.
Argus raises Cardinal Health stock price target on strong earnings By Investing.com
Argus has raised its price target for Cardinal Health (NYSE:CAH) stock to $309 from $264, maintaining a Buy rating after the company reported strong first-quarter fiscal 2027 results. The healthcare services company exceeded revenue and adjusted earnings per share estimates, leading to an increased fiscal 2027 earnings per share guidance. This positive outlook is further supported by consistent segment profit growth, a focus on specialty markets, strong free cash flows, and a "GREAT" financial health rating from InvestingPro.
We Like Cardinal Health's (NYSE:CAH) Earnings For More Than Just Statutory Profit
Cardinal Health (NYSE:CAH) recently reported strong earnings, which was well-received by the market. Analysis of the accrual ratio revealed a negative value of -2.58 for the year to September 2026, indicating that the company's free cash flow significantly exceeded its reported profit. Additionally, unusual items reduced profit by US$840m, suggesting that without these non-recurring charges, future profits could be higher, leading to an optimistic outlook on Cardinal Health's earnings potential.
Cardinal Health Stock Rides A 6-Day Winning Streak To A 9.7% Gain
Cardinal Health (CAH) stock is on a 6-day winning streak, gaining 9.7% and adding approximately $5.7 billion to its market value, now at $64.4 billion. This surge is primarily driven by company-specific factors rather than broader market movements, with the stock closing at $277.45, its highest in the past year. While revenue growth is strong, operating margins are below the S&P 500 Health Care median.
Cardinal Health Board of Directors Approves Quarterly Dividend
Cardinal Health's Board of Directors has approved a quarterly dividend of $0.5158 per share, payable on January 15, 2027, to shareholders of record as of January 4, 2027. The dividend will be issued from the company's capital surplus. Cardinal Health is a global healthcare services and products company, providing customized solutions across the healthcare industry.
Cardinal Health Approves $0.5158 Quarterly Dividend
Cardinal Health's Board of Directors has approved a quarterly dividend of $0.5158 per share, payable on January 15, 2027, to shareholders of record as of January 4, 2027. This announcement sets the specific amount and timeline for the company's upcoming dividend payment. Cardinal Health (CAH) is a major distributor of pharmaceuticals and medical products, with its shares listed on the New York Stock Exchange.
Cardinal Health (CAH) Stock Could Be Pricey Following Raised Earnings Guidance
Cardinal Health (CAH) has shown strong long-term performance, but its current stock valuation appears rich, trading at 35.3x earnings, which is above the sector average. Recent positive results and raised earnings guidance have pushed the stock to a 52-week high, suggesting much of the good news is already factored into the price. While analysts generally view the stock as "roughly fairly valued" based on its earnings power and cash generation, the premium valuation warrants careful consideration.
Cardinal Health Declares Quarterly Dividend of $0.5158
Cardinal Health's Board of Directors has approved a quarterly dividend of $0.5158 per share, payable on January 15, 2027, to shareholders of record as of January 4, 2027. This decision reflects the company's strong capital management and commitment to shareholder returns. Cardinal Health, a global distributor of pharmaceuticals and medical products, aims to enhance investor confidence and solidify relationships with its shareholders.
A Jan. 15 payout from Cardinal Health gives shareholders 51.58 cents per share.
Cardinal Health (NYSE: CAH) announced that its Board of Directors approved a quarterly dividend of $0.5158 per share, payable on January 15, 2027. Shareholders of record at the close of business on January 4, 2027, will receive the dividend from the company's capital surplus. This decision was announced on November 11, 2026.
Cardinal Health Board of Directors Approves Quarterly Dividend
Cardinal Health's Board of Directors has approved a quarterly dividend of $0.5158 per share, payable on January 15, 2027, to shareholders of record as of January 4, 2027. The company is a global healthcare services and products provider, distributing pharmaceuticals and medical products, and offering various healthcare solutions. This announcement comes as part of its ongoing financial operations.
Is Jim Cramer-backed Cardinal Health’s Dividend Safe?
This article examines the safety of Cardinal Health's (NYSE:CAH) dividend, which is favored by Jim Cramer and listed among his top dividend stocks. Despite a small recent dividend increase, the company's strong operating cash flow, even after accounting for litigation payments, suggests its dividend is secure. The analysis compares Cardinal Health's dividend sustainability to other consumer and pipeline stocks Cramer has discussed, highlighting cash flow as a key indicator.
CVS announces breakup, but its Ohio skeptics say it’s incomplete
CVS recently announced a corporate split into CVS Health and CVS Pharmacy, aiming for increased focus and better customer experience, with completion expected by 2028. However, critics like Antonio Ciaccia argue that the breakup primarily separates less profitable retail operations from lucrative pharmacy benefit management (PBM) and insurance sectors, including high-profit specialty drugs, without addressing core conflicts of interest in healthcare costs. The American Economic Liberties Project views it as an attempt to preempt more substantial reforms, though some believe it eliminates conflicts related to PBM reimbursements to independent pharmacies.
If You Invested $100 In Cardinal Health Stock 5 Years Ago, You Would Have This Much Today
Cardinal Health (NYSE: CAH) has significantly outperformed the market over the last five years, with an annualized return of 40.55%. An investment of $100 in CAH stock five years ago would now be worth $538.08, demonstrating the power of compounded returns. The company currently holds a market capitalization of $63.40 billion.
Henry Schein (NASDAQ:HSIC) Q3 2026: EPS Beat, Guidance Raised
Henry Schein, Inc. (NASDAQ:HSIC) reported strong third-quarter 2026 results, with adjusted earnings per share exceeding analyst expectations and revenue aligning with forecasts. The company raised its full-year non-GAAP earnings guidance, attributing the profit growth to efficiency programs and a shift towards higher-margin specialty products and technology solutions. Despite modest top-line growth, cost management and a richer product mix have significantly boosted profitability.
Cardinal Health stock lifts outlook after strong fiscal Q1
Cardinal Health reported a strong fiscal first quarter, leading to a raised adjusted EPS outlook for fiscal 2027. The company saw significant growth in its Pharmaceutical and Specialty Solutions segment, while the Global Medical Products and Distribution segment remained under pressure. Strategic milestones, including a share repurchase, a CVS Health distribution renewal, and an AdaptHealth acquisition, are expected to support future visibility and growth.
Can Cardinal Health Stock Repeat Its Last Five Years?
Cardinal Health's stock rose significantly by 454.6% over the last five years, largely driven by an increase in its price-to-earnings multiple and a reduction in share count, rather than just sales growth. While sales grew by 54%, explaining about a quarter of the stock's rise, the P/E multiple was the largest contributor, accounting for nearly three-fifths. For the stock to repeat this performance, sales would need to grow at an unsustainable rate of 39.8% annually, as margins and multiples have inherent limits to their expansion.
DataMEDS Completes First Compounded Peptide Sale
DataMEDS AI announced that its Corexa Pharmacy subsidiary has completed its first commercial sale of a compounded peptide, operating under the HHS Enforcement Discretion Policy. The sale involved one of six peptides identified by the FDA's Pharmacy Compounding Advisory Committee, though these compounded drugs are not FDA-approved. The company is developing its pricing model and intends to market these offerings to prescribing physicians.
TD Cowen raises Cardinal Health stock price target on broad profit growth
TD Cowen has increased its price target for Cardinal Health (NYSE:CAH) to $304 from $280, reiterating a Buy rating, citing broad-based profit growth. This follows strong first-quarter fiscal 2027 results and raised full-year guidance, with the stock showing a 33% year-to-date return. InvestingPro analysis suggests the stock is currently undervalued, and Mizuho also raised its price target for Cardinal Health based on strong pharmaceutical distribution and specialty services growth.
Weekly Recap: Albumin revenue falls and Canadian collections restart
Grifols (GRF) reported a decline in albumin revenue for the third quarter and first nine months of 2026, citing a slow recovery in China. Concurrently, the company has begun a phased restart of plasma collection at its 17 Canadian centers after a temporary pause. Grifols also achieved €208 million in third-quarter free cash flow before M&A and does not anticipate an update on its potential U.S. Biopharma IPO review until 2027.
Cardinal Health (CAH) Lifts Guidance As Investors Ask If The Story Is Fully Valued
Cardinal Health (CAH) reported a stronger-than-expected first quarter with increased revenue and earnings, leading to raised fiscal 2027 profit guidance. The company's stock has seen significant gains, though its current valuation is considered fair based on long-term earnings forecasts. However, its high P/E ratio compared to peers suggests investors are already paying a premium for the growth story, prompting questions about future upside potential.
McKesson Q2 Earnings Call Highlights
McKesson (MCK) raised its fiscal 2027 adjusted earnings outlook after reporting strong second-quarter revenue and profit, driven by prescription volumes, specialty distribution, and demand for medication access services. The company now expects adjusted earnings of $45.60 to $46.40 per diluted share and reported an 8% increase in Q2 revenue to $111 billion. McKesson also announced the acquisition of Precision Medicine Group for $2.25 billion and an investment of $1.4 billion for a minority interest in Option Care Health.
Cardinal Health Q1 Earnings Call Highlights
Cardinal Health (CAH) reported strong first-quarter results, prompting an increase in its fiscal 2027 non-GAAP diluted earnings per share outlook. The company saw double-digit profit growth in its pharmaceutical and specialty segment, driven by brand-name drugs and GLP-1 medications, and renewed a key agreement with CVS Health. While the global medical unit faced cost pressures, other growth businesses performed well, leading to increased revenue and profit forecasts for that category.
CAH Q1 Earnings Call Highlights Raised Outlook and Specialty Growth
Cardinal Health, Inc. (CAH) has raised its fiscal 2027 earnings outlook after a strong first quarter, driven by robust specialty pharmaceutical demand, strong generics performance, and growth across its diversified businesses. The company's management highlighted operating discipline, successful long-term customer renewals, and targeted investments, while also addressing pharmaceutical reimbursement changes and pressures in medical distribution. Despite some headwinds like the Inflation Reduction Act, CAH saw significant growth in its pharmaceutical and other business segments, with plans for further expansion in specialty and home-care platforms.
5 insightful analyst questions from McKesson’s Q3 CY2026 earnings call
McKesson reported strong Q3 CY2026 results driven by pharmaceutical distribution and specialty services, with revenue reaching $111 billion and adjusted EPS of $11.68, both beating analyst estimates. The company raised its full-year adjusted EPS guidance. Key analyst questions focused on the integration and impact of recent acquisitions like Precision Medicine Group and Option Care Health, the sustainability of growth in North American Pharmaceutical, and potential effects of 340B policy changes.
Lightning Round: Cardinal Health is a winner, says Jim Cramer
Jim Cramer, host of "Mad Money," offered his opinions on various stocks in a "Lightning Round" segment. He highlighted Cardinal Health as a "winner" and provided insights on companies such as Okta, VF Corp, Trinity Capital, JPMorgan, Ameriprise Financial, D-Wave Quantum, Netflix, Burlington, and Chevron.
Cardinal Health Raises Fiscal 2027 Growth Targets for Two Segments
Cardinal Health has increased its fiscal 2027 earnings outlook, driven by strong first-quarter performance with non-GAAP diluted earnings per share climbing 28%. The company raised its profit-growth forecast for its Pharmaceutical and Specialty Solutions business to 10% to 12% and increased both revenue and profit growth ranges for its "Other" segment. This revised outlook anticipates 17% to 19% growth in non-GAAP diluted EPS from the fiscal 2026 baseline.
Cardinal Health Raises FY2027 Guidance Despite 28% Profit Drop In Medical Products Segment
Cardinal Health increased its fiscal 2027 non-GAAP EPS guidance to $12.80–$13, even as its medical products division experienced a 28% profit decline in the first quarter. The company reported a significant rise in quarterly operating income to $1 billion, driven by strong performance in pharmaceutical and specialty solutions. Additionally, Cardinal Health renewed key CVS pharmacy agreements through 2032, representing nearly two-thirds of its enterprise revenue.
Cardinal Health Raises FY2027 Guidance Despite 28% Profit Drop In Medical Products Segment
Cardinal Health increased its fiscal 2027 non-GAAP EPS guidance to $12.80–$13, following a rise in first-quarter non-GAAP EPS to $3.26, despite a 28% decline in profit from its medical products division. The company's optimistic outlook is attributed to strong performance in pharmaceutical and specialty solutions, as well as other growth businesses. Additionally, Cardinal Health has renewed contracts representing nearly two-thirds of its enterprise revenue over the past year, including a binding letter of intent to renew its CVS pharmacy agreements through 2032.
CAH Q1 Earnings Call Highlights Raised Outlook and Specialty Growth
Cardinal Health, Inc. (CAH) has raised its fiscal 2027 earnings outlook, driven by strong Q1 performance, particularly in specialty pharmaceuticals, generics, and diversified businesses. The company reported adjusted earnings of $3.26 per share and revenues of $67.51 billion, exceeding consensus estimates. Management highlighted sustained pharmaceutical momentum, strengthened customer contract visibility, and strategic expansion in specialty and home-care platforms, despite facing pressures in medical distribution due to elevated petroleum costs.